The role of RB1 and TP53 testing in EGFR-mutated adenocarcinoma, and the use of more aggressive therapy upfront in tumors harboring these alterations is currently under investigation (https://clinicaltrials.gov/ct2/show/NCT03567642). Here, EGFR is linked to adenocarcinoma.